ReviewNeuropsychiatric disease and treatment2023
Pimavanserin: A Truly Effective Treatment for Parkinson's Disease Psychosis? A Review of Interventions.
Review in Neuropsychiatric disease and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 10 citations in OpenAlex.
- Towards treatments targeting the gut to improve behavioural outcomes in autism spectrum disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Persistent Tremor in Bipolar Disorder: A Case Report of Idiopathic Parkinson's Disease Superimposed on Lithium and Antipsychotic Effects.Case reports in psychiatry · 2026Article
- Review
- Multimodal Magnetic Resonance Findings in Parkinson's Disease With "Antecedent Essential Tremor": A Case Series of a Large Kindred.Neuropsychiatric disease and treatment · 2025Article
- Neuropharmacological Interventions of Plant Origin for Parkinson's Disease: A Comprehensive Appraisal.Current neuropharmacology · 2025Review
- Neuropsychiatric disorders in Parkinson's disease.Therapeutic advances in neurological disorders · 2025Review
- Diagnostic and therapeutic challenges in PD-associated non-motor symptoms: the roles of neurologists and consultant physicians.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the second-most common neurodegenerative disorder with a long-term 60% cumulative prevalence of PD psychosis. Medical treatment is limited to few atypical antipsychotic drugs with low affinity to dopamine D2 receptors. In 2016, pimavanserin, a selective 5-HT2A inverse agonist/antagonist, was approved by the US Food and Drug Administration (FDA) as the only treatment for PD psychosis (PDP). This article provides an overview of the epidemiology, pathophysiology, and treatment options for PDP and illuminates the mode of action and therapy options with pimavanserin and the current study data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.